Rhode Island officials are getting used to the idea that the state no longer figures prominently in Amgen's future plans. The biotech giant is cutting hundreds of jobs at a manufacturing facility in the state, and plenty of spare capacity at other manufacturing sites makes Rhode Island an unlikely candidate to produce any new drugs for the company. An undisclosed number of Amgen employees in the state had already accepted early buyouts, raising the impact of the biotech's restructuring.
- check out the report on Amgen
Related Articles:
At corporate HQ, Amgen drops the axe. Report
Amgen discusses the future with analysts. Report
Amgen makes big workforce, budget cuts. Report
Major challenges loom for Amgen. Report
Amgen in crisis? Not us, says CEO Sharer. Report